Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors.

Source: https://www.prnewswire.com/news-releases/compugen-reports-fourth-quarter-and-full-year-2022-results-301756395.html

Part of the hypothesis there is what happens in the periphery and whether depleting effector cells with TIGIT could actually be harmful with FC-competent molecule relative to an FC-nonmolecule.

Source: https://seekingalpha.com/article/4574948-gilead-sciences-inc-gild-q4-2022-earnings-call-transcript?source=feed_all_articles

The TIGIT space is dominated by Roche’s tiragolumab, whose trials and fortunes shape the subsector.

Source: https://seekingalpha.com/article/4657635-mereo-biopharma-lagging-stock-despite-positive-data?source=feed_all_articles